Showing 2411-2420 of 2527 results for "".
- Common Glaucoma Visual Test Lacks Consideration for Central Vision Losshttps://modernod.com/news/common-glaucoma-visual-test-lacks-consideration-for-central-vision-loss/2476195/A common visual field test used to assess severity of glaucoma—the 24-2 visual field (VF) test—may be underestimating the severity of vision loss in many patients, according to a recent study, as reported by
- US Democratic Lawmakers Introduce Bills Targeting Drug Pricinghttps://modernod.com/news/us-democratic-lawmakers-introduce-bills-targeting-drug-pricing/2476197/US lawmakers including Senator Bernie Sanders and Representative Elijah Cummings introduced legislation on Thursday seeking to reduce prescription drug prices. “The United States pays by far the highest prices in the world for prescription drugs,” Sen. Sanders commented, adding “
- Wize Pharma Announces Publication of LOA2 Data on Treatment of Moderately Severe Sjögren’s Syndrome-Related Dry Eyehttps://modernod.com/news/wize-pharma-announces-publication-of-loa2-data-on-treatment-of-moderately-severe-sjogrens-syndrome-related-dry-eye/2476200/Wize Pharma announced publication of data generated in an investigator initiated study conducted in Hungary during 2016, entitled “Treatment of Moderately Severe Sjögren’s Syndrome-Related Dry Eye without Immunomodulation: A Self-Controlled, Unmasked S
- Dompé Announces First Treatment with Oxervate Eye Drops for Neurotrophic Keratitis (NK)https://modernod.com/news/dompe-announces-first-treatment-with-oxervate-eye-drops-for-neurotrophic-keratitis-nk/2476224/Dompé announced the first treatment of a patient with Oxervate eye drops (cenegermin-bkbj) in the United States. Oxervate was approved by the FDA in August 2018 as the first drug specifically indicated to treat neurotrophic keratitis
- ProQR Receives Fast Track Designation from FDA for QR-421a for Usher Syndrome Type 2https://modernod.com/news/proqr-receives-fast-track-designation-from-fda-for-qr-421a-for-usher-syndrome-type-2/2476227/ProQR Therapeutics announced that it received Fast Track designation from the FDA for QR-421a, a first-in-class investigational RNA-based oligonucleotide designed to address the underlying cause of the vision loss associated with Usher syndrome type 2 and non-syndromic retinitis pigmentosa (RP) d
- Focus Vision Supplements Launches Reformulated Version of Omega-3 Focus Relief Plushttps://modernod.com/news/focus-vision-supplements-launches-reformulated-version-of-omega-3-focus-relief-plus/2476228/Covalent Medical, a network of over 385 ophthalmologists who distribute vision supplements sold in practitioners’ offices in the United States under the brand name Focus Vision Supplements, is launching a reformulated version of their leading omega-3 formulation Focus Relief Plus. Focus Re
- Ophthotech Announces the Addition of Calvin W. Roberts, MD, to Its Board of Directorshttps://modernod.com/news/ophthotech-announces-the-addition-of-ophthalmic-industry-leader-calvin-w-roberts-md-to-its-board-of-directors/2476231/Ophthotech Corporation announced the election of Calvin (Cal) W. Roberts, MD, Senior Vice President and Chief Medical Officer, Eye Care at Bausch Health Companies, and Clinical Professor of Ophthalmology at Weill Medical College of Cornell University, to its Board of Directors, effective as of Ja
- Kala Pharmaceuticals Announces NDA for KPI-121 0.25% for Dry Eye Disease Has Been Accepted for Review by FDAhttps://modernod.com/news/kala-pharmaceuticals-announces-nda-for-kpi-121-0-25-for-dry-eye-disease-has-been-accepted-for-review-by-fda/2476240/Kala Pharmaceuticals announced that the new drug application (NDA) for KPI-121 0.25%, a product candidate for the temporary relief of signs and symptoms of dry eye disease utilizing a 2-week course of therapy, has been accepted for review by the FDA. The FDA has set a target action date under the
- Study Suggests CBD May Worsen Glaucoma, Raise Eye Pressurehttps://modernod.com/news/study-suggests-cbd-may-worsen-glaucoma-raise-eye-pressure/2476253/One of the most commonly proposed uses of medical marijuana is to treat glaucoma. But a study from researchers at Indiana University has found that a major chemical component in the substance appears to worsen the primary underpinning of the disease: a rise in pressure inside the eye.
- RayOne Aspheric Fully Preloaded IOL Receives FDA Clearancehttps://modernod.com/news/rayone-aspheric-fully-preloaded-iol-receives-fda-clearance/2479618/Rayner announced that the FDA has cleared the RayOne Aspheric fully preloaded IOL injection system for use in the United States. The FDA granted regulatory clearance of the RayOne Aspheric Monofocal (RAO600C), a fully preloaded aberration-neutral IOL covering a power range of +8.0 D to +34